All In Biotech

NDA 021086 · Cheplapharm

Zyprexa Zydis

Olanzapine · Oral · Atypical Antipsychotic

Last checked: Nov 20, 2026Latest source record: Jan 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Apr 6, 2000

Approved uses

3

Original approval plus efficacy supplements

Registered trials

496

150 Phase 3, 32 recruiting

FAERS reports

108,793

93,787 serious, 13,437 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with...

What it is approved for

From the label in effect Oct 6, 2026.

ZYPREXA ® (olanzapine) is an atypical antipsychotic indicated: As oral formulation for the: Treatment of schizophrenia. ( 1.1 ) Adults: Efficacy was established in three clinical trials in patients with schizophrenia: two 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia ( 14.1 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder and maintenance treatment of bipolar I disorder. ( 1.2 ) Adults: Efficacy was established in three clinical trials in patients with manic or mixed episodes of bipolar I disorder: two 3- to 4-week trials and one maintenance trial. ( 14.2 ) Adolescents (ages 13-17): Efficacy was established in one 3-week trial in patients with manic or mixed episodes associated with bipolar I disorder ( 14.2 ). The increased potential (in adolescents compared with adults) for weight gain and dyslipidemia may lead clinicians to consider prescribing other drugs first in adolescents. ( 1.2 ) Medication therapy for pediatric patients with schizophrenia or bipolar I disorder should be undertaken only after a thorough diagnostic evaluation and with careful consideration of the potential risks. ( 1.3 ) Adjunct to valproate or lithium in the treatment of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 6-week clinical trials in adults ( 14.2 ). Maintenance efficacy has not been systematically evaluated. As ZYPREXA IntraMuscular for the: Treatment of acute agitation associated with schizophrenia and bipolar I mania....

Mechanism: The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • ZYPREXA ZYDIS · OLANZAPINE 20MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • ZYPREXA ZYDIS · OLANZAPINE 10MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • ZYPREXA ZYDIS · OLANZAPINE 15MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB
  • ZYPREXA ZYDIS · OLANZAPINE 5MG · TABLET, ORALLY DISINTEGRATING, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Olanzapine" as an intervention, any sponsor and status, largest first.

All 496 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,554
  • weight increased6,911
  • off label use6,123
  • diabetes mellitus5,418
  • toxicity to various agents4,386
  • drug interaction4,297
  • nausea4,140
  • somnolence4,027
  • fatigue3,681
  • overdose3,489
  • anxiety3,483
  • vomiting3,357

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042,202
20053,180
20063,626
20073,557
20081,873
20093,627
20103,267
20113,309
20122,988
20132,576
20142,974
20158,028
20163,932
20174,830
20186,096
20196,696
20206,173
20216,278
20227,109
20236,892
20247,042
20257,220
20265,317

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zyprexa Zydis (Olanzapine)

2024 spending

$3.0M

Beneficiaries

255

1,766 claims

Per beneficiary

$11,877

$33.69 per unit

View as table
YearSpending
2020$4,230,637
2021$3,792,411
2022$3,550,664
2023$3,475,505
2024$3,028,655

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,214 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.